Marksans Pharma’s wholly owned subsidiary -- Marksans Pharma Inc. has received the final approval for Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA) for Omeprazole Delayed-Release Tablets, 20 mg (OTC).
This product is bioequivalent to the reference listed drug (RLD), Prilosec Delayed-Release Tablets, 20 mg (OTC), of AstraZeneca Pharmaceuticals LP, NDA - 021229. Omeprazole is used to treat heartburn and certain other conditions caused by too much acid in the stomach.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
